In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentActive18 and overPharmaceutical / IndustryD4880C00003
NCT01843374

Trial Description

Summary

This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 180 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, and a 90-day follow-up period.

Further Study Information

This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.

Randomization will be stratified by EORTC status (low-risk vs high-risk), line of therapy (second vs third), and anatomical site (pleural vs peritoneal). This study plans to use the EORTC to stratify subjects into high or low risk groups in order to ensure balanced randomization to the different treatment groups. For subjects in whom pemetrexed was contraindicated or not tolerated or not an approved therapy (eg, peritoneal mesothelioma), prior therapy with a first-line platinum-based regimen is required. Approximately 180 subjects will be enrolled at study centers in multiple countries.

The study consists of a screening period, a treatment period, and a 90-day follow-up period.

Eligibility Criteria

Inclusion criteria:

  • Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma. Disease not amenable to curative surgery;
  • Age 18 and over at the time of consent;
  • ECOG Performance status 0-1;
  • Previous receipt of 1-2 prior systemic chemotherapies that included first-line pemetrexed (or anti-folate)-based regimen in combination with platinum agent;
  • Recovered from all toxicities associated with prior treatment;
  • Measurable disease;
  • Adequate bone marrow, hepatic, and renal function;
  • Negative screening test results for human immunodeficiency virus (HIV), hepatitis A, B and C;
  • Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive authorization in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations;
  • Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product;
  • Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 post last dose.

Exclusion criteria:

  • Received any prior monoclonal antibody against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1);
  • History of chronic inflammatory or autoimmune disease;
  • Active, untreated central nervous system (CNS) metastasis;
  • History of other malignancy unless the subject has been disease-free for at least 3 years. Non-invasive cancer history (such as carcinoma in situ [CIS] that has been resected) is allowed;
  • Pregnant or breast feeding at time of consent;
  • Any condition that would prohibit the understanding or rendering of information and consent and compliance with the requirements of this protocol;
  • Active or history of diverticulitis. Note that diverticulosis is permitted;
  • Active or history of inflammatory bowel disease (eg, colitis, Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosis or Wegener's granulomatosis;
  • History of sarcoidosis syndrome;
  • Currently receiving systemic corticosteroids or other immunosuppressive medications;
  • Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment;
  • The last dose of prior chemotherapy or radiation therapy (with the exception of palliative radiotherapy) was received less than 2 weeks prior to randomization;
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results;
  • Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion);
  • Employees of the study site directly involved with the conduct of the study, or immediate family members of any such individuals.

Trial Contact Information

Trial Lead Organizations/Sponsors

MedImmune, Incorporated

MedImmune Contact
  Email: ClinicalTrialTransparency@astrazeneca.com

Trial Sites

U.S.A.
Arizona
  Scottsdale
 Research Site
California
  La Jolla
 Research Site
  Los Angeles
 Research Site
  San Francisco
 Research Site
  Santa Monica
 Research Site
Delaware
  Newark
 Research Site
Florida
  Tampa
 Research Site
Illinois
  Chicago
 Research Site
  Peoria
 Research Site
Michigan
  Detroit
 Research Site
Minnesota
  Minneapolis
 Research Site
New York
  New York
 Research Site
  Rochester
 Research Site
North Carolina
  Durham
 Research Site
Ohio
  Canton
 Research Site
  Cleveland
 Research Site
Pennsylvania
  Philadephia
 Research Site
Texas
  Houston
 Research Site
Australia
  Nedlands
 Research Site
Australian Capital Territory
  Garran
 Research Site
New South Wales
  Gosford
 Research Site
  Waratah
 Research Site
Queensland
  Auchenflower
 Research Site
  Chermside
 Research Site
Victoria
  Box Hill
 Research Site
  Heidelberg
 Research Site
Belgium
  Leuven
 Research Site
Canada
Ontario
  Toronto
 Research Site
France
  Lille Cedex
 Research Site
Germany
  Hamburg
 Research Site
Italy
  Bergamo
 Research Site
  Rozzano
 Research Site
  Siena
 Research Site
Netherlands
  Eindhoven
 Research Site
  Rotterdam
 Research Site
Republic of South Africa
  Kraaifontein
 Research Site
  Port Elizabeth
 Research Site
  Pretoria
 Research Site
Spain
  Barcelona
 Research Site
  Sabadell
 Research Site
  Sevilla
 Research Site
Sweden
  Linkoping
 Research Site
United Kingdom
  Plymouth
 Research Site
England
  Maidstone
 Research Site
  Wirral
 Research Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01843374
ClinicalTrials.gov processed this data on January 05, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top